Organon & Co. (NYSE:OGN) Reaches New 12-Month High - Still a Buy?

Key Points

• Organon reached a new 52-week high, trading as high as $13.72, with its 50-day and 200-day moving averages at $13.53 and $10.80, respectively.
• Analyst sentiment remains cautious: BNP Paribas Exane and Piper Sandler set $14 price targets, but the consensus rating is “Reduce” with an average target of $11.40.
• Organon declared a quarterly dividend of $0.02, equivalent to an annualized yield of 0.6%, while institutional investors and hedge funds own 77.43% of the company.

Organon & Co. (NYSE:OGN - Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $13.72 and last traded at $13.6750, with a volume of 2158100 shares. The stock had previously closed at $13.70.

Analyst Ratings Changes

OGN has been the subject of a number of research analyst reports. BNP Paribas Exane restated a "neutral" rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Piper Sandler upgraded Organon & Co. from an "underweight" rating to a "neutral" rating and lifted their price target for the company from $5.00 to $14.00 in a report on Tuesday, April 28th. Finally, Weiss Ratings downgraded Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 3rd. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Reduce" and an average price target of $11.40.

Organon & Co. Price Performance

The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. The firm has a market capitalization of $3.59 billion, a price-to-earnings ratio of 17.76, a P/E/G ratio of 1.27 and a beta of 1.55. The stock's 50 day moving average price is $13.53 and its two-hundred day moving average price is $10.80.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $0.02 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.'s payout ratio is 10.39%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Allied Private Wealth LLC bought a new stake in Organon & Co. in the second quarter worth approximately $33,000. Farther Finance Advisors LLC raised its holdings in shares of Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock valued at $31,000 after purchasing an additional 2,033 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Organon & Co. by 69.8% in the 2nd quarter. GAMMA Investing LLC now owns 5,782 shares of the company's stock valued at $78,000 after purchasing an additional 2,376 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Organon & Co. in the 4th quarter valued at $44,000. Finally, Kestra Advisory Services LLC bought a new stake in Organon & Co. in the fourth quarter worth $47,000. 77.43% of the stock is owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source